Tuesday, September 22, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 18, 2026

Is It Time To Reconsider Salesforce (CRM) After This Year’s 32% Share Price Slide?

View original at finance.yahoo.com
“The latest twelve month free cash flow is about $14.27b.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Analyst estimates project Salesforce free cash flow will reach approximately $19.85 billion by 2031

    60% confidence
  • Salesforce's -40.0% return over the last year is lagging behind its peers

    60% confidence
  • Salesforce holds a valuation score of 5 out of 6

    60% confidence
  • Salesforce's trailing twelve month free cash flow is approximately $14.27 billion

    60% confidence
  • Salesforce DCF analysis estimates intrinsic value at approximately $346.09 per share, implying the stock trades at a 49.9% discount and is undervalued

    60% confidence

Data points we hold from this source

Salesforce · cash14.27 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com
Is It Time To Reconsider Salesforce (CRM) After This Year’s 32% Share Price Slide? — Source | Via News | Via News